PARP1抗体;PARP1 Antibody—艾普蒂

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: 293T cells, Primary antibody: P07334(ERG Antibody) at dilution 1/650, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 2 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P07334(ERG Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P07334(ERG Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

Poly(ADP-ribose) polymerase 1 (PARP1) is a nuclear enzyme critical for DNA repair, genome stability, and cellular stress responses. It catalyzes the addition of poly(ADP-ribose) chains (PARylation) to target proteins, facilitating the recruitment of DNA repair machinery to sites of single-strand breaks. PARP1 also regulates processes like chromatin remodeling, transcription, and apoptosis. Dysregulation of PARP1 is linked to cancer, neurodegenerative disorders, and inflammation.

PARP1 antibodies are essential tools for studying its expression, localization, and function. These antibodies are widely used in techniques such as Western blotting, immunofluorescence, immunohistochemistry, and immunoprecipitation to detect PARP1 protein levels or its cleavage products (e.g., during apoptosis). Specific antibodies can distinguish between full-length PARP1 (∼116 kDa) and its caspase-cleaved forms (∼89 kDa), serving as apoptosis markers. Some antibodies also detect PARylation activity, aiding in functional studies of PARP1 inhibition.

In cancer research, PARP1 antibodies help evaluate PARP1 as a biomarker or therapeutic target, particularly in homologous recombination-deficient cancers treated with PARP inhibitors (e.g., olaparib). Commercial PARP1 antibodies vary in specificity, with validation required for each application. Cross-reactivity with PARP family members (e.g., PARP2) should be considered. Overall, PARP1 antibodies remain pivotal in advancing molecular and clinical research on DNA damage response and targeted therapies.